NCT02443506View on ClinicalTrials.gov

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

June 30, 2007

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

AMG 623

Single dose of AMG 623 administered as subcutaneous and intravenous doses

DRUG

Placebo

Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY